HYLAN G-F20

Generic Name: HYLAN G-F20

Clinical Trials

Knee Injection RCT

Phase 4

Terminated

Conditions: Osteoarthritis

Interventions: Drug: Methylprednisolone Acetate Injection
Drug: Ketorolac Tromethamine Injection
Drug: Hylan G-F 20

First Posted Date: 2018-10-03

Last Posted Date: 2020-02-18

Lead Sponsor: UConn Health

Target Recruit Count: 18

Registration Number: NCT03694821

Locations: 🇺🇸
UConn Health, Farmington, Connecticut, United States

Comparison of Single Intra-articular Injection of Hyruan-One With Hylan G-F 20 in Knee Osteoarthritis

Phase 4

Conditions: Knee Osteoarthritis

Interventions: Drug: Hylan G-F 20
Drug: Normal saline
Drug: Hyruan-One

First Posted Date: 2018-03-30

Last Posted Date: 2018-03-30

Lead Sponsor: Thammasat University

Target Recruit Count: 276

Registration Number: NCT03484091

Locations: 🇹🇭
Thammasat University, Khlong Luang, Pathum Thani, Thailand

Outcomes of Injections in Patients Waiting for Total Knee Replacement

Phase 4

Conditions: Osteoarthritis of the Knee

Interventions: Drug: Hylan G-F 20
Drug: Triamcinolone

First Posted Date: 2017-03-27

Last Posted Date: 2017-03-27

Lead Sponsor: Universidade Federal Fluminense

Target Recruit Count: 120

Registration Number: NCT03090698

Locations: 🇧🇷
Hospital dos Servidores do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

Clinical Trial to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis

Phase 3

Completed

Conditions: Coxarthrosis

Interventions: Drug: Platelet rich plasma
Drug: Hylan G-F 20

First Posted Date: 2016-02-29

Last Posted Date: 2019-02-22

Lead Sponsor: Fundación Pública Andaluza Progreso y Salud

Target Recruit Count: 74

Registration Number: NCT02694146

Locations: 🇪🇸
Complejo Hospitalario de Pontevedra, Pontevedra, Spain
🇪🇸
Hospital Universitario Virgen Macarena, Sevilla, Spain

A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis

Phase 2

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: JointStem
Drug: Synvisc-One

First Posted Date: 2016-02-04

Last Posted Date: 2021-08-10

Lead Sponsor: Nature Cell Co. Ltd.

Target Recruit Count: 28

Registration Number: NCT02674399

Locations: 🇺🇸
Orthopedic Pain Specialists, Santa Monica, California, United States

Study of Safety and Efficacy of 6 mL Synvisc-One (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment

Phase 4

Completed

Conditions: Osteoarthritis

Interventions: Drug: Synvisc-One

First Posted Date: 2015-03-17

Last Posted Date: 2017-08-07

Lead Sponsor: Genzyme, a Sanofi Company

Target Recruit Count: 394

Registration Number: NCT02389452

Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee Osteoarthritis

Phase 4

Completed

Conditions: Osteoarthritis

Interventions: Drug: Hylan G-F 20
Drug: Standard treatment
Procedure: Physiotherapy
Procedure: Hydrotherapy

First Posted Date: 2014-07-22

Last Posted Date: 2014-07-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 518

Registration Number: NCT02197026

Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee

Phase 4

Completed

Conditions: Knee Osteoarthritis

Interventions: Drug: Corticosteroid
Drug: Hylan G-F 20

First Posted Date: 2013-06-11

Last Posted Date: 2014-04-22

Lead Sponsor: Thammasat University

Target Recruit Count: 100

Registration Number: NCT01874574

Locations: 🇹🇭
Thammasat University Hospital, Thammasat University, Prathumthani, Thailand

A Study of the Efficacy and Safety of Synvisc® in Chinese Subjects With Symptomatic Osteoarthritis of the Knee(s)

Phase 4

Completed

Conditions: Osteoarthritis

Interventions: Drug: Hylan G-F 20

First Posted Date: 2012-04-26

Last Posted Date: 2016-02-24

Lead Sponsor: Sanofi

Target Recruit Count: 237

Registration Number: NCT01586338

Locations: 🇨🇳
Sanofi-Aventis Administrative Office, Shangai, China

Study of Viscosupplementation for the Treatment of Knee Pain After Menisectomy

Not Applicable

Withdrawn

Conditions: Arthralgia

Interventions: Drug: Hylan G-F 20
Other: Sham Injection

First Posted Date: 2009-09-03

Last Posted Date: 2021-02-25

Lead Sponsor: Grant Jones

Registration Number: NCT00971074

Locations: 🇺🇸
The Ohio State University Sports Medicine Center, Columbus, Ohio, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy